There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?
It may seem difficult to get excited about (NYSE: PFE) these days. After the company brought in record revenue of $100 billion last year thanks to its coronavirus vaccine, Comirnaty, and its COVID antiviral treatment, Paxlovid, the story has changed quite a bit. The pharmaceutical giant recently lowered its expectations for coronavirus product revenue this year as demand declines. And in the third quarter, Pfizer reported a $2.4 billion net loss.
But, before you turn your back on Pfizer stock, it's important to look beyond this dark cloud hanging over the company -- and consider the full picture. Pfizer has reached a turning point, and the highest levels of coronavirus-related revenue may be in the past. But there's actually a silver lining to this cloud, and it could represent growth and billions of dollars in revenue down the road.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Stock
With 29 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a positive potential of 44.65% for Pfizer Inc. compared to the current price of 28.35 €.
